eblanchard@cooley.com
Eric Blanchard practices corporate and securities law. He counsels domestic and foreign public and private companies, with an emphasis on those in the technology and biopharma industries, as well as investment banks. Eric advises clients on a variety of corporate transactions, including initial public offerings, follow-on equity offerings, pre-IPO financings, investment-grade, high-yield and convertible debt offerings, liability management transactions, proxy contests and acquisitions. He also represents public companies with respect to securities and disclosure issues and corporate governance matters.
Download full bio
The Clorox Company – $1.1 Billion Unsecured Senior Notes Offering
Xometry – $287 Million Convertible Senior Notes Offering
SOPHiA Genetics – $234 Million IPO
Xometry – $348 Million IPO
GH Research – $184 Million IPO
View all
Capital Markets
Public Companies
Emerging Companies
Mergers & Acquisitions
Life Sciences
Technology
He has been absolutely brilliant. He is relaxed, measured, on top of all the issues and a delight to deal with.
Catholic University of America, ColumbusJD, magna cum laude, 1999
University of MarylandBA, 1996
New York
The Clorox Company – $1.1 Billion Unsecured Senior Notes Offering May 12, 2022
Legal 500 US 2021 Highlights Cooley July 19, 2021
These Firms Guided Top Real Estate Deals in First Half of 2021 July 8, 2021
Chambers USA: Capital Markets: Debt & Equity
Legal 500: Key Lawyer – Capital Markets: Equity Offerings
+1 212 479 6565
Locations